Company intelligence / Profile preview

NeoLumina Bioscience

Schlieren, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

NeoLumina Bioscience is a Swiss clinical-stage biopharmaceutical company dedicated to developing next-generation psychedelic-inspired therapies for mental health conditions. The company's lead program, NLS-1, is a proprietary formulation of psilocybin currently being evaluated in Phase 2 clinical trials for the treatment of anorexia nervosa. NeoLumina aims to address significant unmet needs in psychiatry by refining the delivery and therapeutic profile of psychedelic compounds to treat complex eating disorders. By focusing on rigorous clinical validation and optimized patient outcomes, the company seeks to integrate these novel treatments into mainstream medical practice for underserved psychiatric populations.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NeoLumina Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoLumina Bioscience.

Explore the full profile